Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1B | O75688 | 2/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
| ▸ | PPP1CC | P36873 | 2/20 | 0.56 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | PPARG | P37231 | 3/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6800576 | 0.88 | FABP7 (0.55) | PPM1BPTPN1PPP1CCTSHRTDP1 | |
| SCHEMBL1664146 | 0.87 | TSHR (0.58) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL1664580 | 0.86 | L3MBTL1 (0.54) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL1663781 | 0.85 | TSHR (0.51) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL1664742 | 0.85 | L3MBTL1 (0.56) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL1663959 | 0.85 | ALDH1A1 (0.56) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL2832823 | 0.84 | PPM1B (0.59) | PPM1BPTPN1PPP1CCTSHRFABP7 | |
| SCHEMBL27783538 | 0.84 | PPM1B (0.71) | PPM1BPTPN1PPP1CCTSHRALDH1A1 | |
| SCHEMBL1663613 | 0.84 | CA1 (0.55) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 | |
| SCHEMBL1663376 | 0.83 | ALDH1A1 (0.51) | TSHRTDP1L3MBTL1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011071674-A1 | ASYMMETRIC CYCLIC DIESTER COMPOUNDS | FERRO CORPORATION (US) | 2011-06-16 | — | — | WO | disclosed |
| US-20100113664-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | FERRO CORPORATION (US) | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312470-A1 | Asymmetric Cyclic Diester Compounds | DDT, PCNA, AADAC | PPM1B 3183/4885PTPN1 3084/4885PPP1CC 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.